🔍 Search
Clinical tool Free

cSCC staging — Brigham & Women's

BWH T-stage outperforms AJCC 8 in most cohorts and is recommended by BAD 2020. Tick the high-risk features that apply.

Tool safetyClinician-support only

This tool supports guideline lookup and documentation. It does not replace MDT discussion, histopathology review or clinician judgement. Confirm features on the histopathology report; local Cancer Alliance pathways take precedence.

Risk features
High-risk perineural invasion — any one of the following counts as the PNI risk factor (BAD 2020 / TNM8)
Result
BWH T1 0 risk factors
Nodal metastasis
< 1%
Death from disease
≈ 0%

Notes

  • Low-risk T1 cSCC — standard surgical excision per BAD 2020.
BWH staging — Jambusaria-Pahlajani et al. JAMA Dermatol 2013;149:402–10.
Important. Educational aid only. Percentages are approximate cohort-level estimates from BWH derivation / validation studies and are not individual risk predictions. MDT-led individualisation required for BWH T2b and T3.

Source basis

  1. This page was launch-reviewed on 19 May 2026. See the source-control register for the NICE, NHS England, BAD, RCPath, WHO, AJCC / TNM and pivotal-trial sources used across the site; check live guidance and local MDT policy before applying recommendations.

Spot a correction?

If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.